AstraZeneca (AZN)
| Bid | 72.94 |
| Market Cap | 226.47B |
| Revenue (ttm) | 107.98B |
| Net Income (ttm) | 14.05B |
| EPS (ttm) | 2.25 |
| PE Ratio (ttm) | 32.46 |
| Forward PE | 14.74 |
| Analyst | Buy |
| Ask | 73.1 |
| Volume | 4,331,011 |
| Avg. Volume (20D) | 5,414,479 |
| Open | 75.05 |
| Previous Close | 74.09 |
| Day's Range | 72.63 - 75.12 |
| 52-Week Range | 62.75 - 87.68 |
| Beta | 0.16 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...
Analyst Forecast
According to 7 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 23.25% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
21 hours ago · proactiveinvestors.co.uk
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bankAstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carr...
4 days ago · proactiveinvestors.co.uk
ANGLE passes key milestone as it completes AstraZeneca assay developmentANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy system to support clinical trials in prostate and mult...
